![]() |
|
|
Vol. 299, Issue 2, 652-658, November 2001
2C-Adrenoceptor-Selective Antagonist
Vascular Biology and Circulation, Maryland Research Laboratories,
Otsuka Maryland Research Institute, Rockville, Maryland
OPC-28326 has been reported to selectively increase femoral blood flow
in open-chest dogs and autoperfused canine femoral artery
preparations. Preliminary data indicated that OPC-28326 has a
high affinity at the
2-adrenoceptor. In the present
study, we tested OPC-28326 in isoflurane anesthetized rats at a dose of
3 mg/kg of body weight, given intraduodenally. OPC-28326 significantly increased femoral blood flow, by 44.7 ± 13.8%, 45 min after drug administration, whereas carotid blood flow increased by only 3.6 ± 5.5% (n = 6). Chinese hamster ovary cell
lines overexpressing rat
2D-,
2B-, or
2C-adrenoceptor were established. These cells also
coexpress luciferase, driven by cAMP elevation. In radioligand binding
assays using cell membrane preparations, OPC-28326 dose dependently
competed with [3H]RX821002 binding, with calculated
Ki values of 3840 ± 887, 633 ± 46, and 13.7 ± 1.9 nM on
2D-,
2B-,
and
2C-adrenoceptor, respectively. A similar affinity
and rank order of potency were also found for OPC-28326 on the
2-subtypes using epinephrine as agonist in luciferase assays. No agonistic effect of OPC-28326 was detected on any of the
2-adrenoceptors. Finally, in situ hybridization
performed on skeletal muscle tissue sections collected from rat hind
limb (musculus gastrocnemius) demonstrated a high level expression of
2C in the vascular tissues. Thus, the abundance of
2C in the skeletal muscle may account for the selective
effect of OPC-28326 in increasing femoral blood flow.